Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
MDXG Mimedx Group Inc
- Stocks
- Healthcare
- NASDAQ: MDXG
Price (delayed)
$7.42
Market cap
$1.1B
P/E Ratio
27.48
Dividend/share
N/A
EPS
$0.27
Enterprise value
$1.01B
MiMedx is an industry leader in utilizing birth tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare.
Highlights
The quick ratio has soared by 58% YoY and by 13% QoQ
Mimedx Group's equity has increased by 30% YoY and by 5% QoQ
Mimedx Group's EPS has decreased by 48% YoY and by 7% QoQ
MDXG's net income is down by 45% YoY and by 5% QoQ
Key stats
What are the main financial stats of MDXG
Market
Valuations
Earnings
Shares outstanding
147.7M
Market cap
$1.1B
Enterprise value
$1.01B
Price to earnings (P/E)
27.48
Price to book (P/B)
5.39
Price to sales (P/S)
3.1
EV/EBIT
18.83
EV/EBITDA
15.92
EV/Sales
2.86
Revenue
$352.38M
Gross profit
$288.73M
Operating income
$53.31M
Net income
$40.18M
EBIT
$53.53M
EBITDA
$63.32M
Free cash flow
$64.6M
Per share
Balance sheet
Liquidity
EPS
$0.27
EPS diluted
$0.27
Free cash flow per share
$0.44
Book value per share
$1.38
Revenue per share
$2.39
TBVPS
$1.63
Total assets
$270.42M
Total liabilities
$67.64M
Debt
$18.66M
Equity
$202.78M
Working capital
$157.49M
Debt to equity
0.09
Current ratio
4.7
Quick ratio
3.96
Net debt/EBITDA
-1.39
Margins
Efficiency
Dividend
EBITDA margin
18%
Gross margin
81.9%
Net margin
11.4%
Operating margin
15.1%
Return on assets
15.9%
Return on equity
21.6%
Return on invested capital
50.8%
Return on capital employed
23.5%
Return on sales
15.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MDXG stock price
How has the Mimedx Group stock price performed over time
Intraday
6.3%
1 week
17.41%
1 month
8.16%
1 year
3.06%
YTD
-22.87%
QTD
-2.37%
Financial performance
How have Mimedx Group's revenue and profit performed over time
Revenue
$352.38M
Gross profit
$288.73M
Operating income
$53.31M
Net income
$40.18M
Gross margin
81.9%
Net margin
11.4%
The net margin has contracted by 47% YoY and by 7% from the previous quarter
MDXG's net income is down by 45% YoY and by 5% QoQ
The operating margin has contracted by 10% from the previous quarter
The operating income fell by 9% QoQ but it rose by 6% YoY
Price vs fundamentals
How does MDXG's price correlate with its fundamentals
Growth
What is Mimedx Group's growth rate over time
Valuation
What is Mimedx Group stock price valuation
P/E
27.48
P/B
5.39
P/S
3.1
EV/EBIT
18.83
EV/EBITDA
15.92
EV/Sales
2.86
Mimedx Group's EPS has decreased by 48% YoY and by 7% QoQ
The stock's price to earnings (P/E) is 35% more than its last 4 quarters average of 20.4
Mimedx Group's equity has increased by 30% YoY and by 5% QoQ
The P/B is 9% lower than the last 4 quarters average of 5.9
The P/S is 11% higher than the 5-year quarterly average of 2.8 but 3.1% lower than the last 4 quarters average of 3.2
MDXG's revenue is up by 5% YoY
Efficiency
How efficient is Mimedx Group business performance
Mimedx Group's return on equity has shrunk by 79% YoY and by 11% QoQ
MDXG's ROA has shrunk by 55% YoY and by 10% QoQ
MDXG's return on invested capital is up by 22% year-on-year but it is down by 7% since the previous quarter
Mimedx Group's return on sales has increased by 14% YoY but it has decreased by 10% QoQ
Dividends
What is MDXG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MDXG.
Financial health
How did Mimedx Group financials performed over time
The quick ratio has soared by 58% YoY and by 13% QoQ
The current ratio has increased by 43% year-on-year and by 12% since the previous quarter
The debt is 91% less than the equity
Mimedx Group's equity has increased by 30% YoY and by 5% QoQ
MDXG's debt to equity is down by 25% year-on-year and by 10% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.